Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
CBP501 is a peptide drug that inhibits the activity of several kinases responsible for phosphorylation of CDC25C, including MAPKAP-K2, C-Tak1, and CHK1, resulting in disruption of the G2 checkpoint and potentially leading to cell-cycle arrest and increased tumor cell death (PMID: 17237275, PMID: 29088764).
|DrugClasses||CHK1 Inhibitor 15|
|CAS Registry Number||565434-85-7|
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|
|Bleomycin + CBP501||Bleomycin CBP501||0||0|
|CBP501 + Cisplatin||CBP501 Cisplatin||0||1|
|CBP501 + Cisplatin + Nivolumab||CBP501 Cisplatin Nivolumab||0||2|